On November 6th, a reporter from Beijing Business Daily learned at the 7th CIIE that Abbott will launch the world's first truly synchronized dual chamber wireless pacemaker, which uses Abbott's unique i2i communication technology to achieve interconnection communication between the two devices in the room and room for the treatment of bradycardia.
It is reported that as an innovator in the global medical and health field, Abbott has gradually landed in the Chinese market through hundreds of innovative life technologies showcased at the CIIE, transforming from exhibits to medical and health products that are well used by the Chinese public. Among them, the AVEIRTM VR single chamber implantable leadless cardiac pacemaker, which made its debut at the 5th CIIE, has been officially approved for market in China, bringing a new treatment option for patients with bradycardia.
The HeartMate 3 implantable left ventricular assist system, which is the world's first and currently the only one to receive three authoritative certifications from the National Medical Products Administration (NMPA), the European Union CE, and the US Food and Drug Administration (FDA), has also been approved for market and recently welcomed its first implantation, providing a new treatment option for advanced heart failure patients in China and improving survival rates and quality of life. At the same time, Abbott's domestically produced immune module Alinity i and automated assembly line GLP have also been officially launched, helping the innovative diagnostic and treatment resources of "Made in China" to cover more regions.